New treatment approach for preventing relapse in people recovering from opioid use disorder
Combination Therapeutic for Chronic Opioid Use Disorder Relapse
This study is testing a new treatment for people recovering from opioid use disorder by combining a low dose of naltrexone with CBD in a special delivery system to help reduce cravings and make recovery easier and safer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aphios Corporation NIH-funded |
| Lab location | 1 site (Woburn, United States) |
| Project ID | NIH-10706844 on NIH RePORTER |
What this research studies
This research aims to develop a new combination therapy for individuals recovering from opioid use disorder (OUD) by using a low-dose naltrexone and cannabidiol (CBD) formulation. The therapy will be delivered through biodegradable polymer nanospheres, which enhances the effectiveness and reduces side effects. The study builds on previous findings that suggest CBD can help reduce cravings and improve treatment adherence. By combining these two compounds, the research seeks to provide a more effective and safer option for patients struggling with OUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are in recovery from opioid use disorder and seeking additional support to prevent relapse.
Not a fit: Patients who are not recovering from opioid use disorder or those who are not interested in pharmacological interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for preventing relapse in individuals recovering from opioid use disorder.
How similar studies have performed: Previous studies have shown promising results with the use of CBD in reducing cravings and improving treatment outcomes in opioid use disorder, indicating that this approach has potential based on existing evidence.
Where this research is happening
Woburn, United States
- Aphios Corporation — Woburn, United States (Active)
Researchers
- Principal investigator: Castor, Trevor P. — Aphios Corporation
- Study coordinator: Castor, Trevor P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.